Diabetes mellitus (DM), a global disease that significantly impacts public health, has become increasingly common over time. In this review, we aim to determine the potential benefits of St. John’s Wort (SJW) as an adjunct therapy for DM. We gathered information from studies conducted in vitro, in vivo, and in humans. In vitro studies investigated the concentrations of SJW extracts capable of inhibiting certain enzymes or factors involved in the inflammatory pathway, such as the β-signal transducer and activator of transcription 1, nuclear factor κB, methylglyoxal, and oxidative stress (OS). The extract was found to have positive effects on OS and anti-inflammatory properties in DM, suggesting it could serve as a protective agent against diabetic vascular complications, cell damage, and apoptosis. According to in vivo research, the essential components of the extract can stimulate thermogenesis in adipose tissue, inhibit several key inflammatory signaling pathways, and delay the early death of pancreatic β cells, all of which contribute to combating obesity. The extract may also help treat prediabetes and significantly reduce neuropathic pain. Human studies have also confirmed some of these results. However, some of the plant’s side effects need further investigation through clinical research before it can be used to treat DM.
Background/Objectives: Advanced glycation end-products (AGEs) are implicated in the vascular complications of type 2 diabetes mellitus (T2DM). Although the Mediterranean diet (MD) confers well-recognized benefits, adherence among people with T2DM is moderate. Evidence regarding the relationship between adherence to the MD and AGEs remains limited. This study aimed to investigate the association between adherence to the MD and AGE levels in individuals with T2DM in Greece. Methods: Adults with T2DM were enrolled in this cross-sectional study. Ocular and skin AGEs were assessed using autofluorescence techniques, while serum AGEs were quantified using an enzyme-linked immunosorbent assay (ELISA). MD adherence was scored with the Mediterranean Diet Score (MedDietScore) (range 0–55). Results: Sixty-one individuals were studied (mean age: 65 ± 9 years; 35 men). Median glycated hemoglobin (HbA1c) and MedDietScore were 6.95 (6.2–7.5)% and 29.0 (27.5–31.5), respectively. Higher adherence to the MD was more frequent among women (p = 0.019) and was associated with lower HbA1c levels (p = 0.002). MedDietScore was inversely correlated with HbA1c (ρ = −0.437, p < 0.001), ocular AGEs (ρ = −0.435, p = 0.013), and skin AGEs (ρ = −0.309, p = 0.033). In multivariable regression analyses, higher adherence to the MD was independently associated with lower ocular (p = 0.043) and skin AGEs (p = 0.005). Conclusions: Higher adherence to the MD was associated with female sex and lower HbA1c. MedDietScore was inversely related to skin, and ocular AGE levels in individuals with T2DM.